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Based on more than 70^^years of antibacterial drug development, an attractive alternative is to reassess unexploited and underutilised structural scaffolds of proven antibacterial potency and resistance-breaking properties, and to develop these further by using cutting-edge synthetic biology.
Antibiotics such as tetracyclines (TCs), which were formerly highly-effective against both Gram-positive and Gramnegative pathogens, are now ineffective owing to widespread antibiotic resistance. [4] TCs are bacteriostatic; the first major class of therapeutics to be termed broad-spectrum antibiotic.
[5] Clinically-important TCs, such as doxycycline, minocycline, and glycylcyclines (a new class of TCs), are termed typical TCs. Their mode of action involves binding to the ribosome during polypeptide elongation to inhibit translation.
[6] Chelocardin (CHD, 3; Figure^^1^b<figr1>), which is produced by Amycolatopsis sulphurea, [7] is regarded as a structurally atypical TC and shows bactericidal activity.
[8]
Initial data on the mode of action of CHD exist, but the exact mechanism of action has yet to be elucidated. [8,^9] CHD is effective against many multidrug-resistant pathogens, including some difficult-to-treat Gram-negative bacteria.
Importantly, it is also effective against TC-resistant strains, except for Pseudomonas aeruginosa (Table^^1<xtabr1>). [10] No toxicity from CHD was observed following oral administration in rats or dogs. [11] In a small pumps). Additional studies to define the mechanisms of resistance to CHD and CDCHD are currently ongoing in our laboratories in order to understand the bacterial strategies used to escape their effects.
Although the enzymatic mechanisms leading to carboxyamido moiety formation in TCs is of medicinal interest, [16,^18] our study is, to the best of our knowledge, the first successful heterologous expression of the AT and AMT from the otc cluster to derive a novel malonamate-primed molecule. The addition of this carboxyamido moiety significantly increases the biological activity of CHD. The acetate-primed impurity of OTC, ADOTC (2), also shows a tenfold reduction in antibacterial activity. [19] Our findings for CHD are thus in agreement with the structure--activity relationships (SAR)
found in typical TC antibiotics.
[14]
Our current understanding of the priming reactions in type^^II PKSs, which mostly involve minimal PKS ketosynthase complexes [13,^20] and an additional auxiliary acyltransferase (AT), is still limited, particularly when considering applying combinatorial approaches to generate potentially useful compounds.Reconstitution of the OTC minimal PKS in a heterologous host resulted in the biosynthesis of a truncated polyketide initiated with acetate. The addition of oxyD alone to this artificial system was sufficient to produce the amidated derivative as the major product. [16] Thus suggesting that rather than being an acyltransferase, OxyP is a thiolase that suppresses priming by acetate by removing the competing acetyl units, as similarly observed in other type^^II PKS systems. [21] However, in contrast to the priming steps in OTC biosynthesis, [13] where the AMT oxyD alone is sufficient for the efficient production of OTC, when only oxyD was expressed in 
Figure^^2
Priming steps in OTC biosynthesis (a) [13] and CHD biosynthesis (b), [15] and proposed malonamate priming in CDCHD biosythesis (c). The starter unit in OTC biosynthesis is indicated in red, the CHD structure in blue, and OTC in black.
Figure^^3
Significant HMBC and COSY correlations of CDCHD. [a]^^MIC=minimal inhibitory concentration.
